LitCovid-sentences  

PMC:7212965 / 6155-7801 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T34 0-44 Sentence denotes Table 1 Summary of Best Practice Statements:
T35 45-96 Sentence denotes Consultative Management of Coronavirus Disease 2019
T36 97-110 Sentence denotes Statement no.
T37 111-120 Sentence denotes Statement
T38 121-503 Sentence denotes 1 In outpatients with new-onset diarrhea, ascertain information about high-risk contact exposure; obtain a detailed history of symptoms associated with COVID-19, including fever, cough, shortness of breath, chills, muscle pain, headache, sore throat, or new loss of taste or smell; and obtain a thorough history for other Gl symptoms, including nausea, vomiting, and abdominal pain.
T39 504-713 Sentence denotes 2 In outpatients with new-onset Gl symptoms (eg, nausea, vomiting, abdominal pain, and diarrhea), monitor for symptoms associated with COVID-19, as GI symptoms may precede COVID-related symptoms by a few days.
T40 714-791 Sentence denotes In a high COVID-19 prevalence setting, COVID-19 testing should be considered.
T41 792-1005 Sentence denotes 3 In hospitalized patients with suspected or known COVID-19, obtain a thorough history of GI symptoms (ie, nausea, vomiting, abdominal pain, and diarrhea), including onset, characteristics, duration, and severity.
T42 1006-1149 Sentence denotes 4 There is presently inadequate evidence to support stool testing for diagnosis or monitoring of COVID-19 as part of routine clinical practice.
T43 1150-1290 Sentence denotes 5 In patients (outpatients or inpatients) with elevated LFTs in context of suspected or known COVID-19, evaluate for alternative etiologies.
T44 1291-1516 Sentence denotes 6 In hospitalized patients with suspected or known COVID-19, obtain baseline LFTs at the time of admission and consider LFT monitoring throughout the hospitalization, particularly in the context of drug treatment for COVID-19
T45 1517-1646 Sentence denotes 7 In hospitalized patients undergoing drug treatment for COVID-19, evaluate for treatment-related Gl and hepatic adverse effects.